Table 3.
Co-infection of HPV with HSV-2, UU, CT, and NG among men in Guangzhou, South China, 2012–2023.
| Variable | HSV-2 |
UU |
CT |
NG |
||||
|---|---|---|---|---|---|---|---|---|
| Total tested | Positive (%) | Total tested | Positive (%) | Total tested | Positive (%) | Total tested | Positive (%) | |
| Total | ||||||||
| HPV negative | 80 | 29 (36.25) | 1137 | 466 (40.99) | 711 | 80 (11.25) | 466 | 13 (2.79) |
| HPV positive | 62 | 29 (46.77) | 885 | 358 (40.45) | 508 | 82 (16.14) | 431 | 6 (1.39) |
| p-value | .206 | .809 | .013 | .146 | ||||
| Asymptomatic | ||||||||
| HPV negative | 26 | 0 | 624 | 263 (42.15) | 370 | 46 (12.43) | 271 | 5 (1.85) |
| HPV positive | 6 | 1 (16.67) | 272 | 97 (35.66) | 164 | 25 (15.24) | 90 | 1 (1.11) |
| p-value | .415 | .069 | .377 | .637 | ||||
| Anogenital warts | ||||||||
| HPV negative | 5 | 2 (40.00) | 63 | 24 (38.10) | 43 | 8 (18.6) | 33 | 0 (0) |
| HPV positive | 26 | 9 (34.62) | 409 | 166 (40.59) | 238 | 39 (16.39) | 248 | 1 (0.4) |
| p-value | .999 | .707 | .72 | .715 | ||||
| Balanoposthitis | ||||||||
| HPV negative | 40 | 28 (70.00) | 183 | 67 (36.61) | 119 | 15 (12.61) | 92 | 7 (7.61) |
| HPV positive | 35 | 27 (77.14) | 134 | 58 (43.28) | 69 | 10 (14.49) | 72 | 3 (4.17) |
| p-value | .485 | .23 | .713 | .558 | ||||
| Male infertility | ||||||||
| HPV negative | 9 | 2 (22.22) | 220 | 80 (36.36) | 174 | 6 (3.45) | 38 | 4 (10.53) |
| HPV positive | 6 | 4 (66.67) | 96 | 39 (40.63) | 61 | 7 (11.48) | 33 | 0 |
| p-value | .237 | .472 | .042 | .161 | ||||
| Others | ||||||||
| HPV negative | 6 | 0 | 94 | 52 (55.32) | 39 | 13 (33.33) | 43 | 1 (2.33) |
| HPV positive | 3 | 0 | 72 | 39 (54.17) | 31 | 9 (29.03) | 35 | 2 (5.71) |
| p-value | – | .882 | .355 | .439 | ||||
HPV, human papillomavirus; HSV-2, herpes simplex virus type 2; UU, Ureaplasma urealyticum; CT, Chlamydia trachomatis; NG, Neisseria gonorrheae.